Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

NCT00729898 · clinicaltrials.gov ↗

COMPLETED

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: biphasic insulin aspart 30

Sponsor

Novo Nordisk A/S